Results 201 to 210 of about 840,940 (292)
Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity
Molecular Oncology, EarlyView.This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert +16 morewiley +1 more sourceMyocardial Late Enhancement With Photon-Counting Detector CT in Spontaneous Coronary Artery Dissection: Prospective Comparison With Cardiac MRI. [PDF]
Invest RadiolKlambauer K, Klotz E, Moser LJ, Kälin T, Biondo A, Schweiger V, Mergen V, Lisi C, Würdinger M, Schlenker R, Di Vece D, Gotschy A, Reiner M, Ghadri JR, Wilzeck VC, Eberhard M, Templin C, Manka R, Alkadhi H. +18 moreeuropepmc +1 more sourceSS-HPT nanocarrier delivery of Hif-1α-shRNA reduces pathological lactylation and alleviates inflammation in a sustained hypoxia mouse model
Yubing Zeng, Yongxiang Wei, Chen Chen, Jinying Shen, Jin Qian, Xiaolin Ma, Mengrui Su, Ting Zhang, Bingran Yu, Chunmei Zhu, Shan Wang +10 moreopenalex +1 more sourcePredictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia
Molecular Oncology, EarlyView.This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Ezgi June Olgac, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman +17 morewiley +1 more sourceRole of Preoperative CEA, CA 19-9, NLR and PLR as Predictors of Adverse Prognostic Pathological Features of Gastric Carcinoma Patients in a Tertiary Centre of Nepal
, 2019 Rajesh Kumar Mandal, Ramesh Bhandari, Paleswan Joshi Lakhey, Yogendra Singh, Pradeep Vaidya, Prasan BS Kansakar, Bikal Ghimire, Bishnu Prasad Kandel +7 moreopenalex +2 more sourcesFeasibility of a ctDNA multigenic panel for non‐small‐cell lung cancer early detection and disease surveillance
Molecular Oncology, EarlyView.Plasma‐based detection of actionable mutations is a promising approach in lung cancer management. Analysis of ctDNA with a multigene NGS panel identified TP53, KRAS, and EGFR as the most frequently altered, with TP53 and KRAS in treatment‐naïve patients and TP53 and EGFR in previously treated patients.Giovanna Maria Stanfoca Casagrande, Marcela de Oliveira Silva, Mariana Bisarro dos Reis, Rodrigo de Oliveira Cavagna, Luciane Sussuchi, Icaro Alves Pinto, Natalia Zampieri Pontes, Rodrigo Sampaio Chiarantano, Flavio Augusto Ferreira da Silva, Pedro de Marchi, Letícia Ferro Leal, Rui M. Reis +11 morewiley +1 more sourceThe detection of bacteria and matrix proteins on clinically benign and pathologic implants [PDF]
, 2019 Adams, Adams, Albesharat, Arrecubieta, Barbieri, Bartsich, Bowden, Brown, Burkhardt, Cohen, Constantine, Deva, Deva, DiEgidio, Dolen, Drinane, Drinane, Ellis, Flores-Mireles, Flores-Mireles, Flores-Mireles, Flugstad, Galdiero, Gerlach, Giordano, Giot, Hieken, Hu, Jacombs, Jacombs, Kalas, Kane, Moser, Moyer, Paek, Paharik, Pajkos, Perez, Poppler, Prantl, Rieger, Rieger, Rosen, Sabaté Brescó, Samen, Spaulding, Tamboto, Urbaniak, Urbaniak, Walker, Wolfram, Xu, Zdolsek +52 morecore +2 more sourcesAggressive prostate cancer is associated with pericyte dysfunction
Molecular Oncology, EarlyView.Tumor‐produced TGF‐β drives pericyte dysfunction in prostate cancer. This dysfunction is characterized by downregulation of some canonical pericyte markers (i.e., DES, CSPG4, and ACTA2) while maintaining the expression of others (i.e., PDGFRB, NOTCH3, and RGS5).Anabel Martinez‐Romero, Ane Martinez‐Larrinaga, Joaquim Grego‐Bessa, Saioa Garcia‐Longarte, Hielke van Splunder, Ianire Astobiza, Amaia Ercilla, Laura Bozal‐Basterra, Isabel Mendizabal, Pilar Villacampa, Arkaitz Carracedo, Mariona Graupera +11 morewiley +1 more source
